Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

Peaceouty Jan. 26 at 8:20 PM

$GSIT $CANF $VVOS Libtard stocks. That’s where the profit is at! $TSLA $MSFT Are compromised by morons.

0 · Reply

Ishowspeed1 Jan. 24 at 2:31 PM

$CANF On watch

0 · Reply

Tryingtoretire01 Jan. 22 at 3:13 PM

$CANF https://ir.canfite.com/news-events/press-releases/detail/1101/can-fite-completes-patient-enrollment-in-phase-2a

0 · Reply

DARKP00L Jan. 20 at 12:10 PM

$CANF 07:09 on Jan. 20 2026 Can-Fite Completes Patient Enrollment In Phase 2a Pancreatic Cancer Trial Of Namodenoson, With Top-Line Efficacy Data Expected In Q3 2026 #tradeideas

0 · Reply

Luke83 Jan. 15 at 2:41 PM

$BYND $CANF $EVTV 💪💪💪

0 · Reply

GeeJoon Jan. 12 at 10:03 AM

$CANF they said in may 2025 that they secured 145m fund for phase 3 and manufacturing, be careful of massive dilution, they will probably issue 30m more shares at this price level to get that funding

1 · Reply

Franknugenixthomas Jan. 11 at 6:13 AM

@Guazabara everyone needs to follow this account!!!!!!!! Jesus thoughts and gains!!!!!!! Just look at $CANF !!!!

1 · Reply

GeeJoon Jan. 9 at 1:49 AM

$CANF 1. it is impossible for micro biotech to commercialise a drug without the help of big pharma, listing the company only for capturing other people's money to fulfil the dream of those doctors/scientists 2. biotech always exaggerate drug efficacy and understimate the time and cost of trial 3. if a drug is good enough to threaten the benefit of industry, big pharma would acquire it asap like in P1/P2, if no one show interest after completing P2, the drug is not novel technology in big pharma's eyes

0 · Reply

GeeJoon Jan. 8 at 12:21 AM

$CANF is it can-fite listed in two marketz, us and israel? so the market cap should be added together, 12m now

1 · Reply

GeeJoon Jan. 8 at 12:10 AM

$CANF im new to this board, why this so cheap with ongoing p3 drug? any hidden problem?

0 · Reply

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Dec 16, 2025, 9:19 AM EST - 6 weeks ago

Can-Fite Provides Update on Clinical and Financial Status

Nov 20, 2025, 7:00 AM EST - 2 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Aug 28, 2025, 8:47 AM EDT - 5 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Jul 30, 2025, 7:04 AM EDT - 6 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 28, 2025, 12:24 PM EDT - 6 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 7:00 AM EDT - 6 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Apr 17, 2025, 8:55 AM EDT - 10 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 14, 2025, 2:28 PM EDT - 10 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Mar 20, 2025, 9:45 AM EDT - 11 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 19, 2025, 9:00 AM EDT - 11 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 3, 2025, 6:00 AM EST - 11 months ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Jan 30, 2024, 7:00 AM EST - 2 years ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 29, 2024, 7:00 AM EST - 2 years ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Dec 20, 2023, 7:00 AM EST - 2 years ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 4, 2023, 7:00 AM EST - 2 years ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Nov 30, 2023, 7:00 AM EST - 2 years ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Peaceouty Jan. 26 at 8:20 PM

$GSIT $CANF $VVOS Libtard stocks. That’s where the profit is at! $TSLA $MSFT Are compromised by morons.

0 · Reply

Ishowspeed1 Jan. 24 at 2:31 PM

$CANF On watch

0 · Reply

Tryingtoretire01 Jan. 22 at 3:13 PM

$CANF https://ir.canfite.com/news-events/press-releases/detail/1101/can-fite-completes-patient-enrollment-in-phase-2a

0 · Reply

DARKP00L Jan. 20 at 12:10 PM

$CANF 07:09 on Jan. 20 2026 Can-Fite Completes Patient Enrollment In Phase 2a Pancreatic Cancer Trial Of Namodenoson, With Top-Line Efficacy Data Expected In Q3 2026 #tradeideas

0 · Reply

Luke83 Jan. 15 at 2:41 PM

$BYND $CANF $EVTV 💪💪💪

0 · Reply

GeeJoon Jan. 12 at 10:03 AM

$CANF they said in may 2025 that they secured 145m fund for phase 3 and manufacturing, be careful of massive dilution, they will probably issue 30m more shares at this price level to get that funding

1 · Reply

Franknugenixthomas Jan. 11 at 6:13 AM

@Guazabara everyone needs to follow this account!!!!!!!! Jesus thoughts and gains!!!!!!! Just look at $CANF !!!!

1 · Reply

GeeJoon Jan. 9 at 1:49 AM

0 · Reply

GeeJoon Jan. 8 at 12:21 AM

$CANF is it can-fite listed in two marketz, us and israel? so the market cap should be added together, 12m now

1 · Reply

GeeJoon Jan. 8 at 12:10 AM

$CANF im new to this board, why this so cheap with ongoing p3 drug? any hidden problem?

0 · Reply

GeeJoon Jan. 7 at 11:03 AM

$CANF what the main holder %？ only 3million market cap?

0 · Reply

Bazzzigar Jan. 6 at 10:43 PM

$CANF SAVA

0 · Reply

1AMBITIOUSSAVAGE Jan. 6 at 9:26 PM

$VCIG earnings soon with revenue Lots of $$$$$$$.$$ To be made $INTS as well $CANF could be triple digits by end of 2026 Lots in pipeline 🚀

0 · Reply

mmerryweather Jan. 6 at 6:15 PM

$CANF DJI + S&P 500 averages at ALL TIME in HISTORY highs! Can you imagine what happens when there is a 3% to 7% very normal down turn in the two averages? The "CON CON-fite" will be $2.95 to $3.20. Will be a buyer in this general area for a trade only. Until then - it will just keep getting ugly for existing shareholders with $25.00 and $35.00 current adjusted cost basis. Have fun all!

0 · Reply

mmerryweather Jan. 6 at 3:49 PM

$CANF Can you imagine what "CON-CON Fite" management is thinking? "We screwed the shareholders again and the stock just will not come off HISTORICAL ALL TIME lows. - Does everyone know all we do is screw shareholders and take their money to pay salaries?" Buyer at $3.05 to $3.20 per share for a quick trade and nothing more. Have a great day children.

0 · Reply

mmerryweather Jan. 6 at 3:06 PM

$CANF And DOWN you go! Down YOU go but not me! $3.65 last trade or DOWN 14.9% so far today - but still early. Where is "peaceoutofmymind" or "BlackBerril?" Both of these posters know EVERYTHING but have been totally wrong on everything they ever posted. Will be a buyer at $3.25 or in that area. Have a good one children.

0 · Reply

mmerryweather Jan. 5 at 8:58 PM

$CANF I am poster "peaceoutofmymind" and have a $50.00 account. I have no idea why anything happens as I have no financial background or understanding. Nothing I have posted has ever been correct and I have no idea how Sabby Management operates on a daily basis or any other time for that matter. I now own 10 shares of CANF in total and have a $32.00 split adjusted cost basis. I have been killed and will continue to get killed until my $50.00 account is dead. Please - someone help me.

0 · Reply

Peaceouty Jan. 5 at 7:41 PM

$CANF All the fake sell offs today was the work of Sabby. Hold and they’ll buy back. Buy and it’ll squeeze.

0 · Reply

Moneyboy231 Jan. 5 at 7:00 PM

$CANF will spike

0 · Reply

mmerryweather Jan. 5 at 5:36 PM

$CANF One other thing! Can someone find out if "peaceoutofhismind" is over the age of 14 and is working with $50.00 or less?

0 · Reply

mmerryweather Jan. 5 at 5:32 PM

$CANF There we go - $4.00 per share and DOWN 9.0% on the day with more downside to come. Can anyone find "BlackBerril" or the moron "pieceoutofhismind" for comment? "Pieceoutofhismond" is the most uneducated poster I have ever encountered. Have fun. See you all at $3.50 or $.175 before the split. Have fun! Dah and Dah!

0 · Reply

GhostOfFrankie4Fingers Jan. 5 at 4:56 PM

$CANF Makes no sense to jump into this with a chart like that.

0 · Reply

Market Cap	5.85M
Revenue (ttm)	670,000.00
Net Income (ttm)	-7.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,176.12%
Debt to Equity Ratio	0.00

Volume	41,263
Avg Vol	630,042
Day's Range	N/A - N/A
Shares Out	1.31M
Stochastic %K	65%
Beta	1.03
Analysts	Sell
Price Target	$70.00